GenSci161 Injection Clinical Trial Application of Changchun High-Tech Subsidiary Accepted by Regulator

Stock News

08/31

Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance Notice issued by the National Medical Products Administration, confirming that the domestic drug registration clinical trial application for the GenSci161 injection has been formally accepted.

Developed independently by Jinsai Pharmaceutical, the GenSci161 injection is a Class 1 therapeutic biological product intended for the treatment of connective tissue disease-associated interstitial lung disease.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1113021196"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113021196\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113021196?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113021196","market":"sh","top_or_hot":-1,"title":"GenSci161 Injection Clinical Trial Application of Changchun High-Tech Subsidiary Accepted by Regulator","media":"Stock News","content":"<p><b>Changchun High-Tech Industry (Group) Co., Ltd.</b> (<b>000661.SZ</b>) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance Notice issued by the National Medical Products Administration, confirming that the domestic drug registration clinical trial application for the GenSci161 injection has been formally accepted.<br><br>Developed independently by Jinsai Pharmaceutical, the GenSci161 injection is a Class 1 therapeutic biological product intended for the treatment of connective tissue disease-associated interstitial lung disease.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GenSci161 Injection Clinical Trial Application of Changchun High-Tech Subsidiary Accepted by Regulator</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenSci161 Injection Clinical Trial Application of Changchun High-Tech Subsidiary Accepted by Regulator\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-08-31 20:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><b>Changchun High-Tech Industry (Group) Co., Ltd.</b> (<b>000661.SZ</b>) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance Notice issued by the National Medical Products Administration, confirming that the domestic drug registration clinical trial application for the GenSci161 injection has been formally accepted.<br><br>Developed independently by Jinsai Pharmaceutical, the GenSci161 injection is a Class 1 therapeutic biological product intended for the treatment of connective tissue disease-associated interstitial lung disease.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDTX","symbol_name":"Corgi MediaTek 2x Daily ETF","start_time":0,"source_url":"","article_id":"1113021196","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113021196","pubTimestamp":1788179298,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDTX":"Corgi MediaTek 2x Daily ETF","BK0046":"生物疫苗","BMED":"iShares Health Innovation Active ETF","BK0028":"国家队","BK0057":"长吉图板块","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK0239":"医药制造","BK0075":"新三板","000661":"长春高新","BK0188":"融资融券","IBBQ":"Invesco Nasdaq Biotechnology ETF","PSYK":"PSYK ETF"},"translate_title":"长春高新子公司GenSci161注射液临床试验申请获监管机构受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDTX":1,"BMED":1,"PSYK":1,"000661":1,"IBBJ":1,"IBBQ":1},"content_text":"Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance Notice issued by the National Medical Products Administration, confirming that the domestic drug registration clinical trial application for the GenSci161 injection has been formally accepted.Developed independently by Jinsai Pharmaceutical, the GenSci161 injection is a Class 1 therapeutic biological product intended for the treatment of connective tissue disease-associated interstitial lung disease.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}